KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic) (2016 - 2025)

Rigel Pharmaceuticals has reported EPS (Basic) over the past 16 years, most recently at $14.88 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 1737.04% year-over-year to $14.88; the TTM value through Dec 2025 reached $20.4, up 1960.61%, while the annual FY2025 figure was $20.4, 1960.61% up from the prior year.
  • EPS (Basic) for Q4 2025 was $14.88 at Rigel Pharmaceuticals, up from $1.55 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $14.88 in Q4 2025 and troughed at -$3.09 in Q4 2022.
  • A 5-year average of $0.86 and a median of -$0.08 in 2021 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): plummeted 2107.14% in 2022 and later surged 5650.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.14 in 2021, then tumbled by 2107.14% to -$3.09 in 2022, then surged by 101.62% to $0.05 in 2023, then skyrocketed by 1520.0% to $0.81 in 2024, then soared by 1737.04% to $14.88 in 2025.
  • Business Quant data shows EPS (Basic) for RIGL at $14.88 in Q4 2025, $1.55 in Q3 2025, and $3.33 in Q2 2025.